Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Mannheim author shares stories of 26 breast cancer survivors in Close to the Chest | CBC News
31+ min ago (604+ words) After Mannheim, Ont., author Tanya Farnan was diagnosed with breast cancer last year, she felt it was important and inspiring to tell the stories of survivors. That's why she curated Close to the Chest, a collection of 26 stories from breast…...
Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer
45+ min ago (144+ words) Sep 13, 2026, 07:46 ET B7-H3-directed antibody-drug conjugate reduced the risk of death by 54% compared with topotecan and improved progression-free survival and response rates At the June 6, 2026 data cutoff, after a median follow-up of 12.2 months, median overall survival was 18.5 months with Ris-Rez compared…...
U.S. Scientists Discover Potential Treatment For Blood Cancer
3+ hour, 33+ min ago (327+ words) In what can be termed as "exciting" news for leukaemia treatment, scientists in Stanford have identified a molecule that can be targeted to this most common form of cancer in childhood. Generally, leukaemia refers to cancer of the White Blood…...
Weight-loss drugs shaping up to be a boon for grocers??? pharmacy units
2+ hour, 31+ min ago (1426+ words) Winnipeg 6° C, Clear While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it’s largely coming from rising sales of weight-loss drugs....
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
12+ hour, 31+ min ago (328+ words) Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 The novel B7-H3-targeted antibody-drug conjugate…...
Professor Li Zhang of Sun Yat-sen University Cancer Center, Guangzhou, China
4+ hour, 46+ min ago (43+ words) (IMAGE) EurekAlert! Professor Li Zhang of Sun Yat-sen University Cancer Center, Guangzhou, China More on this News Release Phase III TAISHAN-302 trial shows Tam-Peli significantly improves survival in relapsed small-cell lung cancer...
Vizag???s AMTZ to Drive BRICS BioDesign Initiative for Healthcare InnovationNews Hello Vizag
8+ hour, 27+ min ago (31+ words) Vizag’s AMTZ to Lead BRICS BioDesign Healthcare Innovation Initiative Hello Vizag Visakhapatnam Decks Up for Ganesh Chaturthi Celebrations Major Tragedy Averted as APSRTC Bus Catches Fire After Passengers Alight in Visakhapatnam...
Ivonescimab significantly improves overall survival versus pembrolizumab in advanced lung cancer
10+ hour, 41+ min ago (13+ words) Medical Xpress...
AstraZeneca Breast Cancer Drug Trial Fails Primary Goal in SERENA-4 Study
3+ hour, 52+ min ago (261+ words) dailypioneer.com AstraZeneca’s breast cancer drug Etcamah fails to achieve primary goal Biopharmaceutical major AstraZeneca has said its Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib did not meet its objective of statistically significant improvement in progression-free…...
Prof. Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
6+ hour, 57+ min ago (47+ words) EurekAlert! Prof. Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. More on this News Release Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC...